Glucose lowering to control macrovascular disease in type 2 diabetes: Treating the wrong surrogate end point?

JAMA

Volumn 300, Issue 17, 2008, Pages 2051-2053

  Goodarzi, Mark O ^a,b   Psaty, Bruce M ^c,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PERINDOPRIL TERT BUTYLAMINE PLUS INDAPAMIDE; PIOGLITAZONE; PRETARAX; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE CONTROL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; TREATMENT OUTCOME; VASCULAR DISEASE; ARTICLE; DIABETIC ANGIOPATHY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE;

EID: 55549094090     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.510     Document Type: Note

References (15)

1. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
2. Port SC, Boyle NG, Hsueh WA, Quinones MJ, Jennrich RI, Goodarzi MO. The predictive role of blood glucose for mortality in subjects with cardiovascular disease. Am J Epidemiol. 2006;163(4):342-351.
3. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
4. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
5. Abraira C, Colwell J, Nuttall F, et al; Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med. 1997;157(2):181-188.
6. Després JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952-957.
7. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25(7):1177-1184.
8. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98(5):398-404.
9. Dandona P, Aljada A, O'Donnell A, Dhindsa S, Garg R. Insulin is an antiinflammatory and anti-atherosclerotic hormone. Metab Syndr Relat Disord. 2004;2(2):137-142.
10. Goalstone ML, Natarajan R, Standley PR, et al. Insulin potentiates plateletderived growth factor action in vascular smooth muscle cells. Endocrinology. 1998;139(10):4067-4072.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes [published online ahead of print September 10, 2008]. N Engl J Med. doi:10.1056/NEJMoa0806470.
13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
14. Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med. 2004;47(4):564-574.
15. Kronmal RA, Barzilay JI, Tracy RP, Savage PJ, Orchard TJ, Burke GL. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab. 2004;89(6):2852-2858.